Drugs, Diseases, and the Managed Care Impact

(D3) Novel Therapies for Plaque Psoriasis: Aligning the Patient Perspective with Disease Management

Wednesday, March 22, 2023

3:15 PM – 4:30 PM

Location: 301AB

ACPE UAN:0233-0000-23-014-L01-P | Contact Hours: 1.25 | Activity Type: Knowledge-based

Faculty(s)

Kayla Braestrup, PharmD, BCACP

Clinical Pharmacy Specialist – Dermatology and Gastroenterology
Kaiser Foundation Health Plan of the Northwest
Portland, OR
Leah M. Howard, JD

President & CEO
National Psoriasis Foundation
Alexandria, VA
Lynsey Smith, PharmD, BCACP

Clinical Pharmacy Specialist in Drug Use Management: Dermatology, Gastroenterology, Rheumatology
Kaiser Foundation Health Plan of Colorado
Denver, CO

Moderator(s)

RN

Robert Nordyke, PhD

VP
National Pharmaceutical Council
Washington

This activity is supported by an educational grant from Arcutis Biotherapeutics, Inc.

Plaque psoriasis disease severity ranges from mild cutaneous to extensive body surface area and multi-organ involvement, yet individuals with mild disease report a high disease burden and significant impact on physical and mental functioning. Advances in understanding the immune-mediated components of plaque psoriasis are driving targeted treatment approaches, adding to the complexity of formulary decisions and pharmacy benefit design. This session will focus on the impact of plaque psoriasis, defining the value of treatment options from the patient perspective, clinical evidence for novel therapies, and managed care considerations to optimize access to appropriate treatment.

Learning Objectives::

At the completion of this activity, participants should be able to:

Define plaque psoriasis disease burden and the value of treatment outcomes from the patient perspective.
Review the evidence supporting novel plaque psoriasis therapies.
Discuss managed care benefit design challenges and strategies to optimize access to appropriate treatment.